PVR and neoplasm: In order to specifically target the NK cell population, we incorporated the UL141 gene from human cytomegalovirus into VSV, which specifically inhibits the NK cell-activating ligand CD155, resulting in enhanced virus propagation and tumor responses corresponding to inhibition of NK and NKT cell migration to infected tumor sites (91).